Adamas Pharmaceuticals (ADMS) recently reported their Q2 earnings with a substantial beat on both EPS and revenue despite an ongoing pandemic. The market did respond appropriately, with the stock trading up nearly 50% following the press release. Unfortunately, the stock is still down over the past 12 months and continues to trade under cash value. After several months of dredging the bottom for hard support, it looks as if the company's commercial progress might provide enough thrust to get the share price dislodged from its purgatory and moving towards fair value.
I intend to review